Shilpa Medicare has appointed Dr. Sridevi Khambhampaty as the Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited, a wholly-owned subsidiary of the company. With more than two decades of experience in the biologics industry, Dr. Khambhampaty has developed products for markets in India, the U.S., and the EU. She is renowned for her technical expertise and leadership, having built high-performing teams throughout her career. Her deep knowledge of biologics development, regulatory compliance, and manufacturing, coupled with strong business acumen, positions her to lead Shilpa Biologics through its next phase of growth, according to a company statement filed with the BSE.
Dr. Khambhampaty holds a Ph.D. in Biophysics from NCBS-TIFR Bangalore and completed a postdoctoral fellowship at Stanford University, California. She brings over 22 years of techno- commercial expertise, with experience at organizations like the Lymphoma & Leukemia Research Foundation, Dr. Reddy’s, and Intas Pharmaceuticals. Her most recent position was at Syngene International Ltd.
Shilpa Medicare recently received U.S. FDA approval for its second NDA [505(b)(2)] injectable product, Bortezomib Injection, for subcutaneous or intravenous use. Bortezomib is available in a 3.5 mg/1.4 mL single-dose vial (2.5 mg/mL).
As an integrated pharmaceutical company, Shilpa Medicare focuses on oncology and non- oncology APIs, peptides, polymers, differentiated finished dosage forms, and a strong biological portfolio. The company also offers comprehensive CDMO services to global pharmaceutical companies, leveraging its R&D and manufacturing capabilities spread across four R&D units and seven manufacturing facilities.
